Comparative Pharmacology
Head-to-head clinical analysis: FARESTON versus TOREMIFENE CITRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FARESTON versus TOREMIFENE CITRATE.
FARESTON vs TOREMIFENE CITRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective estrogen receptor modulator (SERM) that competitively binds to estrogen receptors, exerting antiestrogenic effects in breast tissue.
Nonsteroidal estrogen receptor antagonist; binds to estrogen receptors (ER) with high affinity, competitively inhibiting estrogen binding and exerting antiestrogenic effects. Also possesses weak estrogenic agonist activity.
60 mg orally once daily.
60 mg orally once daily
None Documented
None Documented
The terminal elimination half-life of toremifene is approximately 5 days (range 2-10 days). The half-life of its main metabolite, N-desmethyltoremifene, is about 11 days. This long half-life supports once-daily dosing.
About 5 days for the parent compound; clinical context: steady-state achieved in ~4 weeks
FARESTON (toremifene) is extensively metabolized in the liver. Excretion is primarily fecal (approximately 70%) with renal excretion accounting for less than 10% of the dose as unchanged drug and metabolites.
Primarily fecal (biliary excretion) as metabolites; approximately 10% renal
Category C
Category C
Selective Estrogen Receptor Modulator
Selective Estrogen Receptor Modulator